| MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes (NCT01273181) | National Cancer Institute (NCI) | 2010-12-01 |
| MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy (NCT01239355) | National Cancer Institute (NCI) | 2010-12-01 |
| Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma (NCT01208454) | National Cancer Institute (NCI) | 2010-12-01 |
| RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma (NCT01189240) | National Cancer Institute (NCI) | 2010-12-01 |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer (NCT01280058) | National Cancer Institute (NCI) | 2010-12-01 |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer (NCT01120236) | National Cancer Institute (NCI) | 2010-12-01 |
| Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer (NCT01255150) | National Cancer Institute (NCI) | 2010-12-01 |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma (NCT01330173) | National Cancer Institute (NCI) | 2010-12-01 |
| Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas (NCT01258868) | National Cancer Institute (NCI) | 2010-12-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer (NCT01238133) | National Cancer Institute (NCI) | 2010-12-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma (NCT01122901) | National Cancer Institute (NCI) | 2010-12-01 |
| RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01251172) | National Cancer Institute (NCI) | 2010-12-01 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma (NCT01258998) | National Cancer Institute (NCI) | 2010-12-01 |
| Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer (NCT01270438) | National Cancer Institute (NCI) | 2010-12-01 |
| Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors (NCT01240538) | National Cancer Institute (NCI) | 2010-12-01 |
| Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma (NCT01342757) | National Cancer Institute (NCI) | 2010-12-01 |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT01267240) | National Cancer Institute (NCI) | 2010-12-01 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (NCT01260714) | National Cancer Institute (NCI) | 2010-12-01 |
| Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT01278615) | National Cancer Institute (NCI) | 2010-12-01 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery (NCT01276496) | National Cancer Institute (NCI) | 2010-12-01 |
| Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia (NCT01271283) | National Cancer Institute (NCI) | 2010-12-01 |
| F-18 Sodium Fluoride in Prostate Cancer (NCT01240551) | National Cancer Institute (NCI) | 2010-11-30 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (NCT01254578) | National Cancer Institute (NCI) | 2010-11-24 |
| Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas (NCT01222754) | National Cancer Institute (NCI) | 2010-11-23 |
| Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01251874) | National Cancer Institute (NCI) | 2010-11-22 |
| Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors (NCT01217437) | National Cancer Institute (NCI) | 2010-11-22 |
| AT13387 in Adults With Refractory Solid Tumors (NCT01246102) | National Cancer Institute (NCI) | 2010-11-19 |
| Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (NCT00972478) | National Cancer Institute (NCI) | 2010-11-15 |
| EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors (NCT01251926) | National Cancer Institute (NCI) | 2010-11-15 |
| A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes (NCT01251913) | National Cancer Institute (NCI) | 2010-11-12 |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer (NCT01218867) | National Cancer Institute (NCI) | 2010-11-10 |
| Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma (NCT01239368) | National Cancer Institute (NCI) | 2010-11-10 |
| Apheresis of Patients With Immunodeficiency (NCT01212055) | National Cancer Institute (NCI) | 2010-11-08 |
| Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer (NCT01413750) | National Cancer Institute (NCI) | 2010-11-08 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (NCT01256385) | National Cancer Institute (NCI) | 2010-11-01 |
| Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01222689) | National Cancer Institute (NCI) | 2010-11-01 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy (NCT01220609) | National Cancer Institute (NCI) | 2010-11-01 |
| Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer (NCT01245205) | National Cancer Institute (NCI) | 2010-11-01 |
| RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer (NCT01208441) | National Cancer Institute (NCI) | 2010-11-01 |
| Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma (NCT01239316) | National Cancer Institute (NCI) | 2010-11-01 |
| A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma (NCT01248455) | National Cancer Institute (NCI) | 2010-11-01 |
| Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis (NCT01078454) | National Cancer Institute (NCI) | 2010-11-01 |
| Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer (NCT01236547) | National Cancer Institute (NCI) | 2010-10-28 |
| An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas (NCT01240577) | National Cancer Institute (NCI) | 2010-10-26 |
| Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... (NCT01229150) | National Cancer Institute (NCI) | 2010-10-26 |
| Imaging in MGUS, SMM and MM (NCT01237054) | National Cancer Institute (NCI) | 2010-10-17 |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery (NCT01229943) | National Cancer Institute (NCI) | 2010-10-15 |
| Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (NCT01081262) | National Cancer Institute (NCI) | 2010-10-12 |
| Low-Cost Molecular Cervical Cancer Screening Study (NCT01231945) | National Cancer Institute (NCI) | 2010-10-11 |
| RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia (NCT01236586) | National Cancer Institute (NCI) | 2010-10-08 |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas (NCT01193842) | National Cancer Institute (NCI) | 2010-10-06 |
| Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency (NCT01176006) | National Cancer Institute (NCI) | 2010-10-05 |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (NCT01233505) | National Cancer Institute (NCI) | 2010-10-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma (NCT01120275) | National Cancer Institute (NCI) | 2010-10-01 |
| Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (NCT01383447) | National Cancer Institute (NCI) | 2010-10-01 |
| Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel (NCT01260688) | National Cancer Institute (NCI) | 2010-10-01 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (NCT01204476) | National Cancer Institute (NCI) | 2010-10-01 |
| Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers (NCT01229111) | National Cancer Institute (NCI) | 2010-10-01 |
| Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma (NCT01222715) | National Cancer Institute (NCI) | 2010-10-01 |
| Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer (NCT01232829) | National Cancer Institute (NCI) | 2010-10-01 |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies (NCT01243359) | National Cancer Institute (NCI) | 2010-10-01 |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV (NCT01166126) | National Cancer Institute (NCI) | 2010-10-01 |
| Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01238146) | National Cancer Institute (NCI) | 2010-10-01 |
| Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia (NCT01111292) | National Cancer Institute (NCI) | 2010-10-01 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery (NCT01206140) | National Cancer Institute (NCI) | 2010-10-01 |
| Curcumin in Treating Patients With Familial Adenomatous Polyposis (NCT00641147) | National Cancer Institute (NCI) | 2010-10-01 |
| Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) (NCT01207687) | National Cancer Institute (NCI) | 2010-10-01 |
| RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer (NCT01149356) | National Cancer Institute (NCI) | 2010-10-01 |
| AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT01253447) | National Cancer Institute (NCI) | 2010-10-01 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT01167712) | National Cancer Institute (NCI) | 2010-09-27 |
| A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin (NCT01182285) | National Cancer Institute (NCI) | 2010-09-24 |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (NCT01142388) | National Cancer Institute (NCI) | 2010-09-21 |
| Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy (NCT01198158) | National Cancer Institute (NCI) | 2010-09-15 |
| Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer (NCT01208051) | National Cancer Institute (NCI) | 2010-09-09 |
| Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer (NCT01168232) | National Cancer Institute (NCI) | 2010-09-07 |
| RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy (NCT01193868) | National Cancer Institute (NCI) | 2010-09-01 |
| Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer (NCT01198535) | National Cancer Institute (NCI) | 2010-09-01 |
| RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery (NCT01216787) | National Cancer Institute (NCI) | 2010-09-01 |
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer (NCT01255137) | National Cancer Institute (NCI) | 2010-09-01 |
| Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant (NCT01078441) | National Cancer Institute (NCI) | 2010-09-01 |
| 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors (NCT01191216) | National Cancer Institute (NCI) | 2010-09-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors (NCT01218620) | National Cancer Institute (NCI) | 2010-09-01 |
| Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery (NCT01207726) | National Cancer Institute (NCI) | 2010-09-01 |
| Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma (NCT01057121) | National Cancer Institute (NCI) | 2010-08-27 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (NCT01174121) | National Cancer Institute (NCI) | 2010-08-26 |
| Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (NCT01189266) | National Cancer Institute (NCI) | 2010-08-09 |
| Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (NCT01175980) | National Cancer Institute (NCI) | 2010-08-06 |
| Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (NCT01087294) | National Cancer Institute (NCI) | 2010-08-04 |
| Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer (NCT01200810) | National Cancer Institute (NCI) | 2010-08-01 |
| Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (NCT01145508) | National Cancer Institute (NCI) | 2010-08-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma (NCT01196416) | National Cancer Institute (NCI) | 2010-08-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (NCT01198184) | National Cancer Institute (NCI) | 2010-08-01 |
| RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (NCT01193881) | National Cancer Institute (NCI) | 2010-08-01 |
| Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer (NCT01196429) | National Cancer Institute (NCI) | 2010-08-01 |
| RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer (NCT01192763) | National Cancer Institute (NCI) | 2010-08-01 |
| Study of Pregnancy Hormone Concentrations in Urban and Nomadic Mongolian Women (NCT01160549) | National Cancer Institute (NCI) | 2010-08-01 |
| A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors (NCT01176500) | National Cancer Institute (NCI) | 2010-07-28 |
| A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors (NCT01182883) | National Cancer Institute (NCI) | 2010-07-28 |
| Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia (NCT01168219) | National Cancer Institute (NCI) | 2010-07-15 |